News

The trial showed that nearly double the percentage of patients achieved clear or almost clear skin after 12 weeks of treatment with BI 655066 compared to ustekinumab. The

In the randomized, double-blind, placebo-controlled, multi-dose trial, PBI-4050 was found to be safe and well tolerated without any serious adverse events reported. The trial’s objectives were to show

Ichorcumab is developed to mimic the activity of a human antibody which appears to produce an anticoagulated state without predisposition to bleeding. The acquisition of was identified and

In order to fund selected research projects over the course of the five year agreement, the organizations will each contribute about $2m. The deal is the result of

According to the firms, the small molecule HM71224 is ready to enter Phase II and will be examined for the potential treatment of rheumatoid arthritis, lupus, lupus nephritis,

The deal focuses on the production of human cell therapy products and is designed to allow The US firm to access Phase III supplies of ICT-107, manufactured with

The worldwide license agreement builds upon AbbVie’s commitment to pursue transformational disease-modifying therapies in AD. Tau stabilizes proteins that are responsible for the structure and transport in neuronal

The joint commercialization deal is in line with Daiichi’s strategy to expand its US portfolio through strategic alliances, in addition to its internal research and development (R&D) and

These antibodies are directed to DR5, also called as Trail Receptor 2 (TRAIL-R2), an emerging cancer target. As part of the deal, Genmab will pay iDD Biotech an